Showing results (401-410 of 782) with videos related to

Sort By:
Pageof 79
The Lancet. HIV|March 1, 2019
Growth in HIV-1-exposed but uninfected infants treated with lopinavir-ritonavir versus lamivudine: a secondary analysis of the ANRS 12174 trialStéphane Blanche, Thorkild Tylleskär, Marianne Peries, et al.
The Lancet. HIV|February 14, 2021
Long-term virological outcomes in women who started option B+ care during pregnancy for prevention of mother-to-child transmission of HIV in Dar es Salaam, Tanzania: a cohort studyGoodluck W Lyatuu, Shally Z Mwashemele, Roseline Urrio, et al.
The Lancet. HIV|February 22, 2017
Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trialPaul E Sax, Edwin DeJesus, Gordon Crofoot, et al.
The Lancet. HIV|March 6, 2017
Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority studyEdwin DeJesus, Moti Ramgopal, Gordon Crofoot, et al.
The Lancet. HIV|October 4, 2019
Conditional economic incentives to improve HIV prevention and treatment in low-income and middle-income countriesOmar Galárraga, Sandra G Sosa-Rubí
The Lancet. HIV|April 12, 2025
Impact of quasi-elimination of Wuchereria bancrofti on HIV incidence in southwest Tanzania: a 12-year prospective cohort studyInge Kroidl, Thomas F Marandu, Lucas Maganga, et al.
The Lancet. HIV|April 28, 2025
The impact of homelessness and housing insecurity on HIVJulia C Dombrowski, Maria A Corcorran, Tara Carney, et al.
The Lancet. HIV|May 2, 2025
Statin use in HIV: European AIDS Clinical Society guidance for the primary prevention of cardiovascular diseaseJasmini Alagaratnam, Kathrin van Bremen, Georg M N Behrens, et al.
The Lancet. HIV|May 4, 2025
Lateral flow assay-based CD4 cell count testing for advanced HIV diseaseZibusiso Ndlovu, Ana Moore, Esther C Casas, et al.
The Lancet. HIV|May 29, 2025
Safety, pharmacokinetics, and neutralisation activity of PGDM1400LS, a V2 specific HIV-1 broadly neutralising antibody, infused intravenously or subcutaneously in people without HIV-1 in the USA (HVTN 140/HPTN 101 part A): a first-in-human, phase 1 randomised trialKelly E Seaton, Carmen A Paez, Chenchen Yu, et al.
Pageof 79